GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BrightPath Biotherapeutics Co 4594.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

37

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥84,000

FY2017FY2026

Net income

−¥1.30bn

FY2017FY2026

Free cash flow

−¥1.37bn

FY2017FY2026

Shareholders' equity

¥2.37bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥84,000¥1.1m¥72,000¥5.3m¥15.4m¥2.5m¥11.3m¥155.8m¥354.4m¥529.6m
Gross profit¥55,000¥1.1m−¥341,000−¥13.3m−¥23.0m−¥65.3m−¥55.6m¥2.3m¥35.8m¥1.4m
Research and development—¥888.1m¥775.6m¥1.17bn¥1.14bn¥1.41bn¥1.48bn¥1.39bn¥1.15bn¥816.8m
Operating income−¥1.29bn−¥1.16bn−¥1.16bn−¥1.48bn−¥1.48bn−¥1.73bn−¥1.83bn−¥1.69bn−¥1.60bn−¥1.11bn
Net income−¥1.30bn−¥1.15bn−¥1.17bn−¥1.49bn−¥1.48bn−¥1.72bn−¥1.86bn−¥1.88bn−¥1.58bn−¥1.11bn
Diluted earnings per share-9.40-10.19-13.50-23.48-24.09-32.82-37.52-44.83-37.57-29.80

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥2.60bn¥1.12bn¥1.23bn¥1.70bn¥2.77bn¥3.75bn¥3.47bn¥5.30bn¥7.24bn¥5.41bn
Cash and short-term investments¥2.16bn¥810.5m¥1.06bn¥1.53bn¥2.31bn¥3.27bn¥3.02bn¥4.90bn¥6.53bn¥4.95bn
Total liabilities¥236.4m¥195.6m¥251.3m¥133.9m¥239.7m¥211.8m¥239.4m¥208.4m¥285.3m¥207.1m
Debt—¥25.0m¥112.5m—¥87.5m¥87.5m————
Shareholders' equity¥2.37bn¥925.0m¥979.0m¥1.57bn¥2.53bn¥3.54bn¥3.24bn¥5.10bn¥6.95bn¥5.20bn
Shares outstanding139m113m87m63m62m52m50m42m42m37m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥1.37bn−¥1.25bn−¥1.16bn−¥1.20bn−¥1.51bn−¥1.77bn−¥1.78bn−¥1.46bn−¥1.59bn−¥1.07bn
Capital spending−¥591,000−¥1.4m−¥6.2m−¥1.8m−¥17.6m−¥35.3m−¥107.3m−¥175.3m−¥111.6m−¥97.2m
Free cash flow−¥1.37bn−¥1.25bn−¥1.16bn−¥1.21bn−¥1.53bn−¥1.81bn−¥1.89bn−¥1.63bn−¥1.70bn−¥1.16bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥11,000¥51,000——¥33,000¥1.0m¥33,000¥28,000
Gross profit¥9,000¥30,000——¥25,000¥1.0m¥25,000¥21,000
Operating income−¥547.1m−¥338.4m−¥492.0m−¥219.2m−¥245.4m−¥345.2m−¥273.1m−¥215.6m
Net income−¥530.6m−¥349.9m−¥492.4m−¥220.9m−¥241.9m−¥336.1m−¥276.3m−¥208.3m
Diluted earnings per share-3.82-2.52-4.36-1.96-2.14-2.97-3.19-2.41
Total assets¥2.02bn¥2.60bn¥1.37bn¥1.70bn¥1.21bn¥1.12bn¥1.45bn¥1.70bn
Cash and short-term investments¥1.58bn¥2.16bn¥944.4m¥1.25bn¥901.0m¥810.5m¥1.26bn¥1.54bn
Debt—————¥25.0m¥162.5m¥325.0m
Shareholders' equity¥1.82bn¥2.37bn¥1.11bn¥1.53bn¥1.05bn¥925.0m¥1.13bn¥1.23bn

Financial ratios

Data as of 7 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2017
Gross margin65.5%97.2%-473.6%-252.5%-149.5%-2609.0%——
Operating margin-1541667.9%-203898.2%-1619697.2%-28099.8%-9614.6%-69201.4%——
Net margin-1553513.1%-101601.9%-1622336.1%-28137.0%-9632.6%-68675.5%——
Return on equity-55.1%-124.5%-119.3%-94.8%-58.6%-48.6%——
Return on assets-50.1%-102.7%-94.9%-87.3%-53.6%-45.9%——
Free cash flow yield-20.5%-23.0%-27.7%-39.6%-50.5%-69.0%——
Revenue growth-92.6%1473.6%-98.6%-65.7%515.3%-77.8%——
Earnings growth13.4%-1.4%-21.4%0.1%-13.7%-7.4%——
Current ratio15.83x8.14x6.18x21.57x14.60x23.34x——
Debt to equity—0.03x0.11x0.00x0.03x0.02x0.00x—
Equity ratio90.9%82.5%79.6%92.1%91.3%94.4%——
Interest coverage——-833.58x-24322.49x-4092.29x-190.44x-26.73x-81.60x
R&D as a share of sales—78381.6%1077161.1%22130.2%7371.8%56247.7%13140.3%—
Buybacks as a share of market value-22.9%-30.5%-36.8%-2.7%-17.6%-5.8%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-74.8%-49.3%-60.1%
Operating income-4.4%-5.7%2.7%
Net income-4.2%-5.4%2.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin95.0%-190.6%-412.1%-3.5%
Operating margin-201801.0%-77556.2%-33940.1%-818.5%
Net margin-201815.9%-77786.8%-33959.6%-829.3%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-4.0-4.7-3.3-3.7-4.2-3.4-4.8-7.0-5.6-21.3
Price to sales————399.9——84.424.944.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.